Ann: Commencement of Cohort 3 in Phase 1/2 MND Trial, page-39

My one dollar plus valuation refered to my ultimate valuation that I've long held - that is, I don't know the ultimate value of the company once it starts signing up contracts, but whatever it is, it's over a dollar imo (and how could it not be if monepantel is the next gen rapamycin). Your prediction of 1 cent when the company was trading in the three and four cent range in 2019 was before the big mid year rise and clearly a reference to the then sp trend, at least as far as I recall. After all, what else could you have been referring to? Clinical trial success? Commercial deals?